The invention is directed to methods to identify improbable mutations in the heavy or light chain variable domain of an antibody, methods to identify antigens which bind to antibodies comprising such improbable mutations, and methods of using such antigens to induce immune responses.

The invention relates to methods for quantifying a SARS coronavirus in a blood sample of a subject, and for determining a risk for the subject to develop a severe form of the disease or for the disease to worsen.

Described herein are systems and methods for processing at least one biological sample. The systems and methods may process the biological sample, or plurality thereof, using at least one droplet. The droplet, or plurality thereof, may be manipulated using the systems and methods described herein.

The present disclosure provides SARS-CoV-2 spike proteins and trimers containing such spike proteins. The present disclosure also provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2. The proteins, trimers, and antibodies can be used, for example, to detect anti-SARS-CoV-2 antibodies in sample obtained from a subject.

The present invention provides novel monoclonal antibodies or the antigen-binding fragments thereof, which bind to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or angiotensin-converting enzyme 2 (ACE2). Also provided are a pharmaceutical composition and a kit for detecting the presence of SARS-CoV-2 in a sample comprising the novel monoclonal antibody or the antigen-binding fragments thereof. Also disclosed herein are methods for detection or prevention and/or treatment of SARS-CoV-2 or a disease mediated by a disease mediated by ACE2.

In certain aspects, methods are provided for treating a subject having been diagnosed with coronavirus disease 2019 (COVID-19) with a therapeutic agent that inhibits low-density inflammatory neutrophil (LDN) population expressing intermediate levels of CD 16 (CD16.sup.Int). In certain aspects, methods are provided for treating a subject having been diagnosed with coronavirus disease 2019 (COVID-19) with a therapeutic agent that inhibits CD66b+CD16.sup.IntCD11b.sup.IntCD44.sup.lowCD40.sup.+ low-density inflammatory band (LDIB) neutrophil population. In certain aspects, methods are provided for detecting the seventy level of coronavirus disease 2019 (COVID-19) in a subject, comprising measuring the level of CD16.sup.Int low-density inflammatory neutrophil (LDN) in plasma as compared to a control.

In an embodiment, the present disclosure pertains to a method of detecting an analyte from vesicles in a sample. In an additional embodiment, the present disclosure pertains to an analyte detection platform. In a further embodiment, the present disclosure pertains to a sensor. In another embodiment, the present disclosure pertains to a method of detecting an analyte from a sample. In an additional embodiment, the present disclosure pertains to a method of lysing vesicles. In a further embodiment, the present disclosure pertains to a vesicle lysis platform.

The present application is related to a detection device and method for coronavirus and influenza virus. The device comprises a detection module (20), a signal processing circuit (30), a controller (40), a displayer (50), a digital-to-analog conversion circuit (60), and a clock (70). Noticeably, the detection module (20) comprises a sample cell, and a transistor sensor combination integrated in the sample cell and used for measuring different targets. The detection module (20) may comprise a sample cell array to realize simultaneous detection of a plurality of samples to be detected. The detection method comprises the following steps: adding a sample to be detected into a sample cell, reading an electrical signal response of each transistor sensor in the sample cell to judge whether the sample to be detected contains a virus to be detected or not. The present application belongs to the technical field of biological detection.

The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific for a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

Examples are directed to rapid detection test (RDT) devices, apparatuses, and methods of forming RDT devices and/or apparatuses that include detection particles preloaded in a test region. An example RDT apparatus includes a substrate, and a test region disposed on a first portion of the substrate. The test region including: a first set of detection particles that exhibit a first detectable label, and a set of capture agents configured to bind to a target analyte in a biological sample, each of the set of capture agents including a first ligand configured to bind to the target analyte. The RDT apparatus further includes a second set of detection particles that exhibit a second detectable label, wherein each of the second set of detection particles includes a label protein including a second ligand configured to bind to the target analyte.